Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.

Gold R, Giovannoni G, Selmaj K, Havrdova E, Montalban X, Radue EW, Stefoski D, Robinson R, Riester K, Rana J, Elkins J, O'Neill G; SELECT study investigators.

Lancet. 2013 Jun 22;381(9884):2167-75. doi: 10.1016/S0140-6736(12)62190-4. Epub 2013 Apr 4.

PMID:
23562009
2.

Daclizumab for relapsing remitting multiple sclerosis.

Liu J, Wang LN, Zhan S, Xia Y.

Cochrane Database Syst Rev. 2013 Dec 23;(12):CD008127. doi: 10.1002/14651858.CD008127.pub4. Review.

PMID:
24363032
3.

Daclizumab and its use in multiple sclerosis treatment.

Milo R, Osherov M.

Drugs Today (Barc). 2017 Jan;53(1):7-18. doi: 10.1358/dot.2017.53.1.2570979. Review.

PMID:
28387383
4.

Daclizumab for relapsing remitting multiple sclerosis.

Liu J, Wang L, Zhan SY, Xia Y.

Cochrane Database Syst Rev. 2012 Apr 18;(4):CD008127. doi: 10.1002/14651858.CD008127.pub3. Review. Update in: Cochrane Database Syst Rev. 2013;(12):CD008127.

PMID:
22513956
5.

Daclizumab for relapsing remitting multiple sclerosis.

Liu J, Wang L, Zhan S, Tan J, Xia Y.

Cochrane Database Syst Rev. 2010 Jun 16;(6):CD008127. doi: 10.1002/14651858.CD008127.pub2. Review. Update in: Cochrane Database Syst Rev. 2012;4:CD008127.

PMID:
20556791
6.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
7.

Daclizumab: A Review in Relapsing Multiple Sclerosis.

Shirley M.

Drugs. 2017 Mar;77(4):447-458. doi: 10.1007/s40265-017-0708-2. Review.

PMID:
28211007
8.

Natalizumab for relapsing remitting multiple sclerosis.

Pucci E, Giuliani G, Solari A, Simi S, Minozzi S, Di Pietrantonj C, Galea I.

Cochrane Database Syst Rev. 2011 Oct 5;(10):CD007621. doi: 10.1002/14651858.CD007621.pub2. Review.

PMID:
21975773
9.
10.
11.

▼ Daclizumab for MS.

[No authors listed]

Drug Ther Bull. 2017 Feb;55(2):18-21. doi: 10.1136/dtb.2017.2.0454. Review.

PMID:
28183723
12.

Daclizumab high-yield process in the treatment of relapsing-remitting multiple sclerosis.

Preiningerova JL, Vachova M.

Ther Adv Neurol Disord. 2017 Jan;10(1):67-75. doi: 10.1177/1756285616671887. Epub 2016 Oct 19. Review.

13.

Rituximab for relapsing-remitting multiple sclerosis.

He D, Zhou H, Han W, Zhang S.

Cochrane Database Syst Rev. 2011 Dec 7;(12):CD009130. doi: 10.1002/14651858.CD009130.pub2. Review. Update in: Cochrane Database Syst Rev. 2013;12:CD009130.

PMID:
22161445
14.

A critical appraisal of daclizumab use as emerging therapy in multiple sclerosis.

D'Amico E, Messina S, Caserta C, Patti F.

Expert Opin Drug Saf. 2015 Jul;14(7):1157-68. doi: 10.1517/14740338.2015.1032937. Epub 2015 Mar 31. Review.

PMID:
25826609
15.

Review of daclizumab and its therapeutic potential in the treatment of relapsing-remitting multiple sclerosis.

Reardon J, Perumal JS.

Drug Des Devel Ther. 2013 Oct 9;7:1187-93. doi: 10.2147/DDDT.S27766. eCollection 2013. Review.

16.

Spotlight on anti-CD25: daclizumab in MS.

Schippling DS, Martin R.

Int MS J. 2008 Sep;15(3):94-8. Review.

PMID:
18808743
17.

Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis.

Cohan S.

Biologics. 2016 Sep 12;10:119-38. doi: 10.2147/BTT.S89218. eCollection 2016. Review.

18.

Alemtuzumab: a review of its use in patients with relapsing multiple sclerosis.

Garnock-Jones KP.

Drugs. 2014 Mar;74(4):489-504. doi: 10.1007/s40265-014-0195-7. Review.

PMID:
24604792
19.

Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis.

Hartung HP, Aktas O, Boyko AN.

Mult Scler. 2015 Jan;21(1):22-34. doi: 10.1177/1352458514549398. Epub 2014 Oct 24. Review.

20.

The efficacy and safety of daclizumab and its potential role in the treatment of multiple sclerosis.

Milo R.

Ther Adv Neurol Disord. 2014 Jan;7(1):7-21. doi: 10.1177/1756285613504021. Review.

Supplemental Content

Support Center